Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
7(70%)
Results Posted
100%(2 trials)

Phase Distribution

Ph early_phase_1
1
10%
Ph phase_1
7
70%
Ph phase_2
2
20%

Phase Distribution

8

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

10

all time

Status Distribution
Active(8)
Completed(2)

Detailed Status

Recruiting7
Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
7
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (10.0%)
Phase 17 (70.0%)
Phase 22 (20.0%)

Trials by Status

completed220%
not_yet_recruiting110%
recruiting770%

Recent Activity

7 active trials
Showing 5 of 10
not_yet_recruitingphase_1

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

NCT07741643
recruitingearly_phase_1

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
recruitingphase_1

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

NCT04085887
recruitingphase_1

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

NCT03510208
recruitingphase_1

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

NCT03384238
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07741643Phase 1

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Not Yet Recruiting
NCT07493447Early Phase 1

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Recruiting
NCT04085887Phase 1

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

Recruiting
NCT03510208Phase 1

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Recruiting
NCT03384238Phase 1

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Recruiting
NCT03582124Phase 1

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Recruiting
NCT04511078Phase 2

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Recruiting
NCT05945875Phase 1

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Recruiting
NCT03733210Phase 1

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Completed
NCT03405142Phase 2

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10